Dyslipidemia and oxidative stress in sarcoidosis patients

Clinical Biochemistry

Volumn 45, Issue 9, 2012, Pages 677-682

  Ivanišević, Jasmina ^a   Kotur Stevuljević, Jelena ^a   Stefanović, Aleksandra ^a   Jelić Ivanović, Zorana ^a   Spasić, Slavica ^a   Videnović Ivanov, Jelica ^b   Vučinić Mihailović, Violeta ^b   Ilić, Jasmina ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c Health Centre St Luka   (Serbia)

Author keywords

Lipoprotein status; Oxidative stress status; Sarcoidosis

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; METHOTREXATE; PREDNISOLONE; SUPEROXIDE; SUPEROXIDE DISMUTASE; THIOL DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIAGNOSTIC ACCURACY; DYSLIPIDEMIA; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; SARCOIDOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIOXIDANTS; CASE-CONTROL STUDIES; DYSLIPIDEMIAS; ERYTHROCYTES; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; LIPID PEROXIDATION; LIPIDS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; SARCOIDOSIS; SUPEROXIDE DISMUTASE; SUPEROXIDES; TRIGLYCERIDES;

EID: 84861235704     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.03.009     Document Type: Article

References (40)

1. Rothkrantz-Kos S., Van Dieijen-Visser M.P., Mulder P.G.H., Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003, 49:1510-1517.
2. The joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG), Statement on Sarcoidosis. Am J Respir Crit Care Med 1999, 160:736-755.
3. Vuorinen K., Ohlmeier S., Leppäranta O., Salmenkivi K., Myllärniemi M., Kinnula V.L. Peroxiredoxin II expression and its association with oxidative stress and cell proliferation in human idiopathic pulmonary fibrosis. J Histochem Cytochem 2008, 56:951-959.
4. Rahman I., Biswas S.K., Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006, 533:222-239.
5. Boots A.W., Drent M., Swennen E.L.R., Moonen H.J.J., Bast A., Haenen G.R.M.M. Antioxidant status associated with inflammation in sarcoidosis: a potential role for antioxidants. Respir Med 2009, 103:364-372.
6. Koutsokera A., Papaioannou A.I., Malli F., Kiropoulos T.S., Katsabeki A., Kerenidi T., et al. Systemic oxidative stress in patients with pulmonary sarcoidosis. Pulm Pharmacol Ther 2009, 22:603-607.
7. Psathakis K., Papatheodorou G., Plataki M., Panagou P., Loukides S., Siafakas N.M., et al. 8-Isoprostane, a marker of oxidative stress, is increased in the expired breath condensate of patients with pulmonary sarcoidosis. Chest 2004, 125:1005-1011.
8. Lakari E., Pääkkö P., Kinnula V.L. Manganese superoxide dismutase, but not CuZn superoxide dismutase, is highly expressed in the granulomas of pulmonary sarcoidosis and extrinsic allergic alveolitis. Am J Respir Crit Care Med 1998, 158:589-596.
9. Rothkrantz-Kos S., Drent M., Vuil H., De Boer M., Bast A., Wouters E.F., et al. Decreased redox state in red blood cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse 2002, 19:114-120.
10. Winterbourn C.C., Stern A. Human red cells scavenge extracellular hydrogen peroxide and inhibit formation of hypochlorous acid and hydroxyl radical. J Clin Invest 1987, 80:1486-1491.
11. Nadeem A., Masood A., Siddiqui N. Oxidant-antioxidant imbalance in asthma: scientific evidence, epidemiological data and possible therapeutic options. Ther Adv Respir Dis 2008, 2:215-235.
12. Salazar A., Mañá J., Pintó X., Argimón J.M., Hurtado I., Pujol R. Corticosteroid therapy increases HDL-cholesterol concentrations in patients with active sarcoidosis and hypoalphalipoproteinemia. Clin Chim Acta 2002, 320:59-64.
13. Salazar A., Pintó X., Mañá J. Serum amyloid A and high-density lipoprotein cholesterol: serum markers of inflammation in sarcoidosis and other systemic disorders. Eur J Clin Invest 2001, 31:1070-1077.
14. Kotur-Stevuljevic J., Memon L., Stefanovic A., Spasic S., Spasojevic-Kalimanovska V., Bogavac-Stanojevic N., et al. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin Biochem 2007, 40:181-187.
15. Girotti M.J., Khan N., Mc Lellan B.A. Early measurement of systemic lipid peroxidation products in plasma of major blunt trauma patients. J Trauma 1991, 31:32-35.
16. Auclar C., Voisin E. Nitroblue tetrazolium reduction. CRC handbook of methods for oxygen radical research 1985, 123-132. CRC Press, Boca Raton, Fla. R.A. Greenworld (Ed.).
17. Misra H.P., Fridovich I. Chemistry and metabolism of substances of low molecular weight: the role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972, 247:3170-3175.
18. Ellman Gl. Tissue sulfhydryl groups. Arch Biochem Biophys 1952, 82:70-77.
19. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005, 38:1103-1111.
20. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004, 37:277-285.
21. Hamidi Alamdari D., Ghayour-Mobarhan M., Tavallaie S., Reza Parizadeh M., Moohebati M., Ghafoori F., et al. Prooxidant-antioxidant balance as a new risk factor in patients with angiographically defined coronary artery disease. Clin Biochem 2008, 41:375-380.
22. Hamidi Alamdari D., Paletas K., Pegiou T., Sarigianni M., Befani C., Koliakos G. A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem 2007, 40:248-254.
23. Hosmer D.W., Lemeshow S. Assessing the fit of the model. Applied logistic regression 2000, 160-164. NY John Wiley and sons.
24. Lynch R.E., Fridovich I. Permeation of the erythrocyte stroma by superoxide radical. J Biol Chem 1978, 253:4697-4699.
25. Delibas N., Ozcankaya R., Altuntas I. Clinical importance of erythrocyte malondialdehyde levels as a marker for cognitive deterioration in patients with dementia of Alzheimer type: a repeated study in 5-year interval. Clin Biochem 2002, 32:137-141.
26. Bargagli E., Olivieri C., Bennett D., Prasse A., Muller-Quernheim J., Rottoli P. Oxidative stress in the pathogenesis of diffuse lung diseases: a review. Respir Med 2009, 103:1245-1256.
27. Kelly F.J. Vitamins and respiratory disease: antioxidant micronutrients in pulmonary health and disease. Proc Nutr Soc 2005, 64:510-526.
28. Rebeiz T.J., Mahfouz R., Taher A., Charafeddine Kh., Kanj N. Unusual presentation of a sarcoid patient: multiple arterial and venous thrombosis with chest lymphadenopathy. J Thromb Thrombolysis 2009, 28:245-247.
29. Bowler R.P., Crapo J.D. Oxidative stress in airways: is there a role for extracellular superoxide dismutase?. Am J Respir Crit Care Med 2002, 166:S38-S43.
30. Barnes P.J. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011, 163:29-43.
31. Byon C.H., Sun Y., Chen J., Yuan K., Mao X., Heath J.M., et al. Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol 2011, 31:1387-1396.
32. Albano E., Mottaran E., Vidali M., Reale E., Saksena S., Occhino G., et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005, 54:987-993.
33. Albano E., Mottaran E., Occhino G., Reale E., Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 2005, 22(Suppl. 2):71-73.
34. Das K.S., Balakrishnan V., Mukherjee S., Vasudevan D.M. Evaluation of blood oxidative stress-related parameters in alcoholic liver disease and non-alcoholic fatty liver disease. Scand J Clin Lab Invest 2008, 68:323-334.
35. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
36. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143-3421.
37. Ginsberg H.N., Le N.A., Gilbert H.S. Altered high density lipoprotein metabolism in patients with myeloproliferative disorders and hypocholesterolemia. Metabolism 1986, 35:878-882.
38. Mittendorfer B. Sexual dimorphism in human lipid metabolism. J Nutr 2005, 135:681-686.
39. Kizer J.R., Zisman D.A., Blumenthal N.P., Kotloff R.M., Kimmel S.E., Strieter R.M., et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med 2004, 164:551-556.
40. Boizel R., Benhamou P.Y., Lardy B., Laporte F., Foulon T., Halmi S. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 2000, 23:1679-1685.